RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GIULIANI N
Collezione AO Cuneo

Items : 4

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.

2022
AO Cuneo
AOU Città della Salute di Torino

Corradini P; Passamonti F; Antonio Grossi P; Bruno R; Pagano L; Luppi M; Busca A; Giuliani N; Corso A; Mohamed S; Tosi P; Giovanni Della Porta M; Lanza F; Rigacci L; Massimo Lemoli R; Venditti A; Tafuri A; Billio A; Gentile M; Falini B; Turrini M; Chiara Tisi M; Morotti A; Coviello E; Trentin L; Bocchia M; Galimberti S; Cuneo A; Musto P; et alii...

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. in The Lancet. Haematology / Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.

2020
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Corradini P; Pagano L; Bertù L; Corrao G; Grossi PA; Franchi M; Oberti M; Zappasodi P; Visco C; Armiento D; Pane F; Galieni P; Rigacci L; Pinto A; Fava C; Candoni A; Venditti A; Federici AB; Musto P; Marchesi F; Gentile M; Bocchia M; Olivieri A; Di Renzo N; Ferrandina C; Ortu La Barbera E; Selleri C; Scattolin AM; Luppi M; et alii...

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Asti
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Romano A; Sonneveld P; Ria R; Musto P; Liberati AM; Offidani M; Giuliani N; Marchetti M; Mosca-Siez ML; de Fabritiis P; Gobbi M; Ballanti S; Cellini C; Grasso M; Monaco F; Ronconi S; Pescosta N; Di Lullo G; Capra A; Belotti A; Petrucci MT; Boccadoro M; Zambello R; Mina R;